series-c-plus
Stage
1
Investors
About
Redoxis is a contract research organization (CRO) specializing in preclinical drug development and efficacy evaluation for autoimmune diseases. The company provides services such as in vivo, ex vivo, and in vitro studies to assess the efficacy and mechanism of action of therapies, along with biomarker analysis.
Explore Redoxis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.